Press Releases IP Group Plc

Equities

IPO

GB00B128J450

Real-time Estimate Cboe Europe Other stock markets 04:41:34 2024-04-29 am EDT			5-day change	1st Jan Change
49.48 ^GBX	+1.28%		+4.12%	-14.88%

Apr. 23	Alphawave confident in long term growth potential as revenue rises	AN
Apr. 16	Alphawave shares plunge as set to miss annual sales guidance	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IP : Notice of the 2024 Annual General Meeting	Apr. 24	PU
IP : First Light Fusion - First Light Founder moves into new science-focused role with Acting CEO appointed	Apr. 22	PU
IP : Kynos Therapeutics announces positive top line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement	Apr. 22	PU
IP : First Light Fusion solves major engineering challenge in the design of an Inertial Confinement Fusion pilot power plant	Apr. 03	PU
IP : Tissue Regenix Group plc - Final results for the year ended 31 December 2023	Mar. 19	PU
Mission Therapeutics raises GBP25.2 million to progress clinical candidates in the area of mitophagy	Mar. 15	AQ
IP : Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy	Mar. 14	PU
IP : Moa Techology - Moa to develop next-gen bioherbicides in new 10-year commercial partnership with Croda	Mar. 13	PU
IP : Oxford Nanopore Technologies and SeqOne partner to support interpretation of nanopore sequencing in clinical use	Mar. 12	PU
IP : Quantum Dice And HSBC Collaborate On The Use Of QRNGs To Enhance Financial Monte Carlo Simulations	Mar. 05	PU
IP : Oxford Nanopore Technologies plc - Directorate Change	Mar. 01	PU
IP : Oxford Nanopore Technologies plc - Appoints Two Non-Executive Directors	Dec. 19	PU
IP : Ultraleap and Prophesee enter into a strategic partnership to provide industry-first hand tracking on event sensors for AR devices	Dec. 19	PU
IP : Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury	Dec. 14	PU
IP : AccelerComm Expands LDPC Accelerator IP Licenses for 5G Cloud RAN High-Capacity Solutions	Dec. 13	PU
IP : STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference	Dec. 08	PU
IP : Oxford Nanopore Technologies - Nanopore Community Meeting Technology Update	Dec. 07	PU
IP : Crescendo Biologics - Announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC	Dec. 06	PU
IP : Oxford Quantum Circuits - OQC & Classiq Partner to Advance Seamless Quantum Computing and Data Center Convergence	Dec. 05	PU
IP : Quantum Dice And SpeQtral Unveil Quantum Communication Developments With Zenith QRNG For SpeQtral-1 Mission	Nov. 30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IP Group Plc

Equities

IPO

GB00B128J450

Press Releases

Filters